How to Read the Relapse Estimate in a Five-Trial Bupropion–CBT Review

A 2023 meta-analysis estimated a relapse relative risk of 0.91 for bupropion plus cognitive behavioral therapy compared with placebo plus cognitive behavioral therapy. Its 95% confidence interval, 0.78–1.05, included the no-difference value of 1.

Which comparison was tested?

Apuy, Barreto and Merino included five randomized trials with an aggregate sample of 539 participants. Both groups received cognitive behavioral therapy. The comparison therefore concerns adding bupropion within that treatment context; it does not compare medication with no care.

The review defined relapse using urine-metabolite detection in the final weeks of follow-up and required at least ten weeks of follow-up. That operational definition is narrower than every possible meaning of recovery or recurrence.

A null result is not proof of equivalence

The point estimate favored the bupropion group, but the confidence interval included both a lower relapse risk and a small increase. The review did not establish a statistically clear reduction. It also did not prove the interventions were exactly equal.

Relative risk should not be converted into an absolute percentage-point benefit without the corresponding baseline risk. Nor does a group estimate determine whether a particular individual will respond.

A review reanalyzes earlier evidence

The authors identified heterogeneous populations and publication bias as limitations. The review is a synthesis of included trials, not a new independent participant cohort. Reading it alongside an underlying trial adds interpretive context without adding another independent experiment.

These findings describe the historical evidence included in the 2023 review. They do not establish the status of every later treatment study or supply a current prescribing recommendation.

Scientific source

Apuy LFM, Barreto MAB, Merino LAH. Efficacy of bupropion and cognitive behavioral therapy in the treatment of methamphetamine use disorder: a systematic review and meta-analysis. Brazilian Journal of Psychiatry. 2023;45:280–285. doi:10.47626/1516-4446-2022-2979. Based on the supplied review.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Short answer: Detecting an unexpected opioid at trace level does not, by itself, establish that a product contained an active adulterating dose. In a British Columbia drug-checking study, 189 of 8,889 samples not expected to include fentanyl had an unexpected opioid, and 61.4% of those detections were at trace concentration….

Spread the love

Read Article: Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Short answer: No. In coroner data analyzed for a Canadian study, nitazenes were present in 79 of 8,719 Ontario opioid deaths (0.91%) from January 2019 through December 2022. The Toronto subset was 33 of 1,803 opioid deaths (1.83%). These are presence counts in specified death records, not evidence that nitazenes…

Spread the love

Read Article: Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Why a GHB Result May Not Identify the Substance Originally Taken

Short answer: A test that reports GHB does not necessarily identify the substance a person originally took. A scientific review by Busardò and Jones explains that gamma-butyrolactone (GBL) and 1,4-butanediol can convert rapidly to GHB after ingestion. The measured GHB is a real analytical finding, but the starting compound is…

Spread the love

Read Article: Why a GHB Result May Not Identify the Substance Originally Taken

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us